William Blair Starts Jade Biosciences (JBIO) at Outperform

William Blair analyst Matt Phipps initiates coverage on Jade Biosciences (NASDAQ: JBIO) with a Outperform rating.

The analyst comments "We are initiating coverage of Jade Biosciences based on the potential of JADE101 and JADE201 to demonstrate differentiated clinical profiles over similar approved or late-stage assets, warranting meaningful market share despite not being first-to-market in each respective drug class. Our current valuation framework focuses on JADE101 ahead of expected healthy volunteer data in the coming months, which we believe will have strong read-through to future trials in IgA nephropathy (IgAN) patients."

For an analyst ratings summary and ratings history on Jade Biosciences click here. For more ratings news on Jade Biosciences click here.

Shares of Jade Biosciences closed at $14.05 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Freedom Broker Starts Carnival Corporation (CCL) at Buy
• Medtronic, Inc. (MDT) PT Lowered to $101 at Needham